Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 06, 2023, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 06, 2023, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg".